181 related articles for article (PubMed ID: 19179898)
1. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Kawaishi M; Fujiwara Y; Fukui T; Kato T; Yamada K; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Watabe T; Shimoda Y; Arao T; Nishio K; Tamura T; Koizumi F
J Thorac Oncol; 2009 Feb; 4(2):208-13. PubMed ID: 19179898
[TBL] [Abstract][Full Text] [Related]
2. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH
J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549
[TBL] [Abstract][Full Text] [Related]
3. Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma.
Sánchez Hernández A; José Juan O; Vidal Martínez J; Blanco R; Maciá S; Esquerdo Galiana G; Aparisi Aparisi F; Garde Noguera J; Catot S; Losa Gaspá F; García-Piñon F
Clin Transl Oncol; 2015 Apr; 17(4):281-8. PubMed ID: 25236392
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
6. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Najjar F; Al-Massarani G; Banat I; Alammar M
Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
Yamamoto H; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Oncology; 2008; 75(3-4):169-74. PubMed ID: 18827494
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
13. Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: correlation with clinical outcome.
Najjar F; Alammar M; Bachour M; Al-Massarani G
Int J Biol Markers; 2014 Dec; 29(4):e337-44. PubMed ID: 25041783
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719
[TBL] [Abstract][Full Text] [Related]
16. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Novello S; Scagliotti GV; Sydorenko O; Vynnychenko I; Volovat C; Schneider CP; Blackhall F; McCoy S; Hei YJ; Spigel DR
J Thorac Oncol; 2014 Aug; 9(8):1154-61. PubMed ID: 25157768
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
18. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.
Yuan DM; Zhang Q; Lv YL; Ma XQ; Zhang Y; Liu HB; Song Y
Tumour Biol; 2015 Nov; 36(11):9031-7. PubMed ID: 26084612
[TBL] [Abstract][Full Text] [Related]
20. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
